Reuters Health Report

Click to View in Browser 01/24/2014 EU regulator backs Bayer, GSK drugs, knocks back Novartis, Teva LONDON (Reuters) - Europe's drugs regulator gave its backing on Friday for marketing approval to be granted for Bayer's pulmonary hypertension drug Adempas and for GlaxoSmithKline's diabetes medicine Eperzan. Study suggests kids should unplug before sleep NEW YORK (Reuters Health) - Kids who regularly plugged into social networking sites before bedtime reported sleeping nearly an hour less on school nights than those who rarely connected online, a new study shows. Nestle to spend $1 billion on new factories in Mexico LONDON (Reuters) - Nestle plans to invest $1 billion in Mexico over five years, building two new factories and expanding a third in its sixth-biggest market, it said on Friday. GSK diabetes drug set for European approval LONDON (Reuters) - GlaxoSmithKline said on Friday European regulators had given the green light to its once-weekly diabetes drug albiglutide, which it is marketing as Eperzan. Europe assessing if weight affects 'morning after pill' success LONDON (Reuters) - European regulators said on Friday they would assess whether emergency contraceptives, known as the "morning after pill" worked as effectively in women weighing more than 75 kilograms, and whether the warning labels should be changed. EU panel recommends against PTC muscular disorder drug (Reuters) - PTC Therapeutics Inc said a committee of the European Medicines Agency recommended against a conditional approval to its drug for the treatment of a rare muscular disorder, sending its shares down nearly 30 percent in premarket trading. GSK says melanoma combination meets main goal LONDON (Reuters) - GlaxoSmithKline said on Friday the first of its phase three studies into the combination of Tafinlar and Mekinist to treat melanoma, the deadliest form of skin cancer, had met its main goal. Omega-3 intake inversely linked to signs of brain aging NEW YORK (Reuters Health) - Older women with higher levels of omega-3 fatty acids in their blood had slightly less brain shrinkage than women with low fatty acid levels in a new study. India's Ranbaxy hit by FDA product ban at 4th Indian plant WASHINGTON/MUMBAI (Reuters) - Indian drugmaker Ranbaxy Laboratories Ltd faces long delays and high costs in launching big-selling generic drugs in the United States after products from a fourth plant were banned from entering its main market due to manufacturing violations. Novartis to submit more on heart failure drug after EU setback ZURICH (Reuters) - Novartis said it would ask the European health regulator to look at its heart failure drug serelaxin again after the body took an unfavorable position on it Friday. Related Video Entrepreneur cleans up in Gaza Stranded whales refloated in New Zealand The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend